{"entity":{"type":"insider","cik":"0001854586","url":"/insider/0001854586","json_url":"/insider/0001854586.json","name":"Chu Yu-Waye","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":8,"first":"2021-04-20","last":"2026-03-19","span_basis":"filed_date"},"name_variants":[{"name":"Chu Yu-Waye","source":"filing","n_filings":8,"first_seen":"2021-04-20","last_seen":"2026-03-19"}],"transactions":[{"id":5835125,"accession":"0001610717-26-000125","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-26-000125","line_url":"/filing/0001610717-26-000125#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21279.0,"shares_display":"21,279","price_per_share":6.423,"price_display":"6.42","price_state":"stated","total_value":136675.017,"total_display":"136,675.02","total_whole":"136,675","shares_owned_after":189446.0,"shares_owned_after_display":"189,446","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-17","filed_date":"2026-03-19","scope":"insider"},{"id":4928100,"accession":"0001610717-25-000084","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-25-000084","line_url":"/filing/0001610717-25-000084#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4025.0,"shares_display":"4,025","price_per_share":0.599,"price_display":"0.60","price_state":"stated","total_value":2410.975,"total_display":"2,410.98","total_whole":"2,411","shares_owned_after":135725.0,"shares_owned_after_display":"135,725","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-18","filed_date":"2025-03-20","scope":"insider"},{"id":8019694,"accession":"0001209191-23-024820","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-024820","line_url":"/filing/0001209191-23-024820","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2532.0,"shares_display":"2,532","price_per_share":6.574905213270142,"price_display":"6.57","price_state":"stated","total_value":16647.66,"total_display":"16,647.66","total_whole":"16,648","shares_owned_after":140676.0,"shares_owned_after_display":"140,676","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-18","filed_date":"2023-04-19","scope":"insider","n_lines":2},{"id":8324660,"accession":"0001209191-23-002974","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002974","line_url":"/filing/0001209191-23-002974#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7825.0,"shares_display":"7,825","price_per_share":5.24,"price_display":"5.24","price_state":"stated","total_value":41003.0,"total_display":"41,003.00","total_whole":"41,003","shares_owned_after":143208.0,"shares_owned_after_display":"143,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-11","scope":"insider"},{"id":6329477,"accession":"0001209191-22-025159","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-025159","line_url":"/filing/0001209191-22-025159#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4062.0,"shares_display":"4,062","price_per_share":35.37,"price_display":"35.37","price_state":"stated","total_value":143672.94,"total_display":"143,672.94","total_whole":"143,673","shares_owned_after":151033.0,"shares_owned_after_display":"151,033","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-19","filed_date":"2022-04-21","scope":"insider"},{"id":6142533,"accession":"0001209191-22-003166","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-003166","line_url":"/filing/0001209191-22-003166","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Senior VP Clinical Development)","role_mark":"O","role_mark_label":"Officer (Senior VP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3965.0,"shares_display":"3,965","price_per_share":48.50957881462799,"price_display":"48.51","price_state":"stated","total_value":192340.48,"total_display":"192,340.48","total_whole":"192,340","shares_owned_after":122211.0,"shares_owned_after_display":"122,211","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider","n_lines":2},{"id":4747199,"accession":"0001209191-21-069313","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-069313","line_url":"/filing/0001209191-21-069313","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Senior VP Clinical Development)","role_mark":"O","role_mark_label":"Officer (Senior VP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP Clinical Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":51.45972533333333,"price_display":"51.46","price_state":"stated","total_value":385947.94,"total_display":"385,947.94","total_whole":"385,948","shares_owned_after":131161.0,"shares_owned_after_display":"131,161","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2021-12-13","scope":"insider","n_lines":7},{"id":5424554,"accession":"0001209191-21-027545","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-027545","line_url":"/filing/0001209191-21-027545","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001854586","owner_name":"Chu Yu-Waye","owner_display_name":"Chu Yu-Waye","owner_url":"/insider/0001854586","role":"Officer (Senior VP Clinical Development)","role_mark":"O","role_mark_label":"Officer (Senior VP Clinical Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior VP Clinical Development","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3275.0,"shares_display":"3,275","price_per_share":83.30045801526718,"price_display":"83.30","price_state":"stated","total_value":272809.0,"total_display":"272,809.00","total_whole":"272,809","shares_owned_after":64800.0,"shares_owned_after_display":"64,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-16","filed_date":"2021-04-20","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":18,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":18,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":18},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001501989","name":"CytomX Therapeutics, Inc.","url":"/issuer/0001501989","role":"Officer (Chief Medical Officer)","n_filings":2,"first_seen":"2025-03-20","last_seen":"2026-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001434316","name":"FATE THERAPEUTICS INC","url":"/issuer/0001434316","role":"Officer (Chief Medical Officer)","n_filings":6,"first_seen":"2021-04-20","last_seen":"2023-04-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001854586","retrieved_at":"2026-08-26T10:59:43+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}